Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7294411 | 1.00 | CYP19A1 (0.57) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL29129776 | 0.83 | CYP19A1 (0.61) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL17159812 | 0.82 | CYP19A1 (0.80) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL950133 | 0.81 | CYP19A1 (0.62) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL7293708 | 0.81 | CYP19A1 (0.54) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL7293713 | 0.81 | CYP19A1 (0.54) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL3089927 | 0.78 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL15688800 | 0.77 | CYP19A1 (0.71) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL3235365 | 0.75 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL11354103 | 0.75 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5286869-A | Vasodilators and anticoagulants | FUJIREBIO KABUSHIKI KAISHA (JP) | 1994-02-15 | — | — | US | disclosed |
| EP-0403957-A2 | Optical active 1,4-dihydropyridine derivates | FUJIREBIO INC. (JP) | 1990-12-27 | — | — | EP | disclosed |